We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Scancell Holdings Plc | LSE:SCLP | London | Ordinary Share | GB00B63D3314 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 10.10 | 9.70 | 10.50 | 10.10 | 9.975 | 10.10 | 211,828 | 08:00:21 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 5.27M | -11.94M | -0.0129 | -7.83 | 93.71M |
Date | Subject | Author | Discuss |
---|---|---|---|
21/4/2023 11:06 | "I would not worry about the share price " - Odd is it not, that when the share price drops = "the market has it wrong" However, whenever the share price rises a penny or two = '25p next stop / 40p by month end / £1,£6, £8+" are promoted as market certainties. Does it occur to folks, that REALITY is = Whilst YOU 'experts' think YOU are 'playing the market'...the markets are playing (with) YOU. | the real lozan | |
21/4/2023 09:13 | I would not worry about the share price its actually done us a favour another £20,000 worth in ISA .. if you consider as does Vulpes that the share price is derisory then its an opportunity rather than a hinderance. some cant seem to separate that ... they think something is wrong rather than the market has it wrong the market in Scotland voted for SNP .... | inanaco | |
21/4/2023 09:10 | According to Moderna and possible BioN… not necessarily it is true. | golcheja | |
21/4/2023 09:09 | what moderna is doing .. is not really novel ..... because you are basically building a vaccine to the individual ... same as Transgene but they are using a viral vector as per recent posts it becomes novel when you can build a vaccine for the masses that actually works ... | inanaco | |
21/4/2023 09:05 | Yes, modi1 stop the progression when Keytruda was not effective anymore. Yes this is huge. Yes partial reduction was reported at leat with one brave participant. Yes recruiting for cohort 4 , modi1 + CPI is in progress and yes share price is dropping as if all the above is somehow not connected /relevant…insa | golcheja | |
21/4/2023 09:05 | But the way the immune system has not failed .... you have it the wrong way round its the cancer ability to evade the immune system and indeed reinforce the suppressor function of the immune system to effectively shut it down its called the escape phase | inanaco | |
21/4/2023 09:02 | why almost exclusive to RNA ? can you explain this Golcheja ? | inanaco | |
21/4/2023 08:59 | The idea is to inject into the body a substance that is in the cancerous tumor but not in the healthy cell. Tumors undergo genetic mutations and therefore they also secrete proteins that are slightly different from those of normal cells. When does a cancerous tumor thrive? When he manages to hide these changes from the immune system. But if we teach the immune system to recognize the foreign substances in the cancer cell, then it should attack the tumor more effectively | golcheja | |
21/4/2023 08:57 | Cancer vaccines are part of a whole collection of new treatments called "immunotherapy". This field is based on the understanding that the immune system also routinely takes care of eliminating potential cancerous tumors. A problematic cancerous tumor develops in the few cases where the immune system fails in its role. Immunotherapy drugs that have been successful to date, such as Keytruda, take all kinds of approaches to strengthen the activity of the immune system. These drugs are very successful in certain types of cancer and only in some patients. It is not yet known exactly what makes them successful in a certain patient and not in others. | golcheja | |
21/4/2023 08:54 | Big boys… Moderna attacks this problem in a way that is possible almost exclusively with RNA technology for vaccines: it performs genetic sequencing of all the mutations in a particular person's tumor, identifies those that are very different from what is in his healthy cells, and then it prescribes his own personal vaccine. This process takes about a month and a half, but the intention is to speed it up | golcheja | |
20/4/2023 15:43 | Marcus, what big boys are watching Scancell, do you have any evidence ? | panama7 | |
20/4/2023 15:27 | and you posters trust Big Pharma to buy Scancell. The very same Big Pharma working with the WHO to villify and demonise Ivermectin | panama7 | |
20/4/2023 15:18 | 17.2 vs 12.6 months | marcusl2 | |
20/4/2023 15:08 | Maybe after the next RNS but the big boys watching Scancell know already. | marcusl2 | |
20/4/2023 14:45 | Couldn't help myself, topped up | rigga 1 | |
20/4/2023 14:45 | “It’s sort of like a paradigm shift.” question is ... when will the stock market understand that .... | inanaco | |
20/4/2023 12:25 | not sure what Konar and Burble are posting .......... but we are treating patients already that have failed CPI .... get a grip guys .... Burble Posts: 919 Price: 17.125 No Opinion RE: Twitter postToday 12:16 Possibly. If the CPI+Modi-1 shows promise, then there's nothing stopping them changing the protocol or adding a separate sub study to include patients who failed front line CPI. Obv. the only downside to that is costs. | inanaco | |
20/4/2023 12:20 | My guess would be deals for Avidimab, sc2811, SC88 are in the works. Nothing in pharma happens quickly. “The stock market is a device for transferring money from the impatient to the patient.”WB | marcusl2 | |
20/4/2023 12:14 | What we are seeing is a significant increase in the number of deals being done in the Pharma space particularly in relation to Cancer. Let’s see if our large venture capital shareholders can steer such a deal in the direction of SCLP or sell the whole company with all its potential products to one of the big boys. | 888icb | |
20/4/2023 11:52 | What this illustrates is the IR peril of not updating the market when there is a relevant event (such as the conference).Somethin | markingtime |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions